Complete Response of Advanced Melanoma Treated With Talimogene Laherparepvec and Subsequent Sweet's-like Infiltrate

JAMA Dermatol. 2017 Jul 1;153(7):719-721. doi: 10.1001/jamadermatol.2017.0466.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Antineoplastic Agents, Immunological / therapeutic use
  • Biopsy
  • Follow-Up Studies
  • Head and Neck Neoplasms / complications
  • Head and Neck Neoplasms / diagnosis
  • Head and Neck Neoplasms / drug therapy*
  • Humans
  • Immunotherapy / methods*
  • Male
  • Melanoma / complications
  • Melanoma / diagnosis
  • Melanoma / drug therapy*
  • Middle Aged
  • Programmed Cell Death 1 Receptor
  • Remission Induction
  • Scalp*
  • Skin Neoplasms / complications
  • Skin Neoplasms / diagnosis
  • Skin Neoplasms / drug therapy*
  • Sweet Syndrome / complications*
  • Sweet Syndrome / diagnosis

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Immunological
  • Programmed Cell Death 1 Receptor
  • pembrolizumab